TV News LIES

Tuesday, Feb 09th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Federal report: Florida among states with significant drop in uninsured

Drop in uninsured in many statesEight states saw a significant drop last year in the number of residents going without health...

NFL Insists Football Is Safe Even As List Of Players With CTE Grows

NFL ignores CTEThe Super Bowl is a beloved American tradition, with a heavy cash flow that leads back...

Millions could die as world unprepared for pandemics, says UN

pandemicsA global epidemic far worse than the Ebola outbreak is a real possibility and could kill...

Scientists 3D-print bone structure to help tissue regenerate

3-D print bone tissueScientists in England created a 3D-printed bone scaffold that allows blood flow and cell growth to...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!